Literature DB >> 22881361

The role of imaging techniques in the management of multiple myeloma.

Elena Zamagni1, Michele Cavo.   

Abstract

Bone disease is the major feature of multiple myeloma (MM). Imaging is required for correct staging, in the follow-up after treatment and, as recently highlighted, is predictor of prognosis. In the near future, whole-body X-Ray may be replaced by more sensitive techniques, such as whole-body low-dose computerized tomography (CT). Magnetic resonance imaging (MRI) is the gold standard method for assessing bone marrow infiltration of the spine, predicting the risk of vertebral fracture and distinguishing between benign and malignant osteoporosis. Positron emission tomography (PET) with CT (PET/CT) provides important information about the extent of whole-body disease, including soft tissue masses, and is the best tool to distinguish between active or inactive disease after therapy. Both MRI and PET/CT are predictors of clinical outcome. A prospective use of these newer imaging techniques in both clinical trials and clinical practice may help optimize MM management in the near future.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 22881361     DOI: 10.1111/bjh.12007

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  41 in total

Review 1.  The role of positron emission tomography-computed tomography and magnetic resonance imaging in diagnosis and follow up of multiple myeloma.

Authors:  Jo Caers; Nadia Withofs; Jens Hillengass; Paolo Simoni; Elena Zamagni; Roland Hustinx; Yves Beguin
Journal:  Haematologica       Date:  2014-04       Impact factor: 9.941

Review 2.  New criteria for response assessment: role of minimal residual disease in multiple myeloma.

Authors:  Bruno Paiva; Jacques J M van Dongen; Alberto Orfao
Journal:  Blood       Date:  2015-04-02       Impact factor: 22.113

Review 3.  The Critical Role of Imaging in the Management of Multiple Myeloma.

Authors:  Shahzad Raza; Siyang Leng; Suzanne Lentzsch
Journal:  Curr Hematol Malig Rep       Date:  2017-06       Impact factor: 3.952

Review 4.  Multiple myeloma of the spine.

Authors:  Arian Lasocki; Frank Gaillard; Simon J Harrison
Journal:  Neuroradiol J       Date:  2017-04-20

Review 5.  Imaging of multiple myeloma: Current concepts.

Authors:  Thorsten Derlin; Peter Bannas
Journal:  World J Orthop       Date:  2014-07-18

6.  Treatment response evaluation with 18F-FDG PET/CT and 18F-NaF PET/CT in multiple myeloma patients undergoing high-dose chemotherapy and autologous stem cell transplantation.

Authors:  Christos Sachpekidis; J Hillengass; H Goldschmidt; B Wagner; U Haberkorn; K Kopka; A Dimitrakopoulou-Strauss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-08-29       Impact factor: 9.236

7.  Asymptomatic Multiple Myeloma Presenting as a Nodular Hepatic Lesion: A Case Report and Review of the Literature.

Authors:  Hans Huang; Fateh Bazerbachi; Hector Mesa; Pankaj Gupta
Journal:  Ochsner J       Date:  2015

8.  Prognostic significance of increased bone marrow microcirculation in newly diagnosed multiple myeloma: results of a prospective DCE-MRI study.

Authors:  Maximilian Merz; Thomas M Moehler; Judith Ritsch; Tobias Bäuerle; Christian M Zechmann; Barbara Wagner; Anna Jauch; Dirk Hose; Christina Kunz; Thomas Hielscher; Hendrik Laue; Hartmut Goldschmidt; Stefan Delorme; Jens Hillengass
Journal:  Eur Radiol       Date:  2015-07-29       Impact factor: 5.315

Review 9.  ¹⁸F-FDG PET/CT: a review of diagnostic and prognostic features in multiple myeloma and related disorders.

Authors:  Franco Dammacco; Giuseppe Rubini; Cristina Ferrari; Angelo Vacca; Vito Racanelli
Journal:  Clin Exp Med       Date:  2014-09-14       Impact factor: 3.984

10.  Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (C-C motif) ligand 20.

Authors:  B Dalla Palma; D Guasco; M Pedrazzoni; M Bolzoni; F Accardi; F Costa; G Sammarelli; L Craviotto; M De Filippo; L Ruffini; P Omedè; R Ria; F Aversa; N Giuliani
Journal:  Leukemia       Date:  2015-09-30       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.